Section Arrow
VIR.NASDAQ
- Vir Biotechnology
Quotes are at least 15-min delayed:2026/03/05 17:23 EST
After Hours
Last
 9.25
+0.15 (+1.65%)
Bid
9.07
Ask
9.35
High 9.25 
Low 9.07 
Volume 58.83K 
Regular Hours (Closed)
Last
 9.1
-0.465 (-4.86%)
Day High 
9.57 
Prev. Close
9.565 
1-M High
10.94 
Volume 
2.46M 
Bid
9.07
Ask
9.35
Day Low
9.065 
Open
9.35 
1-M Low
6.86 
Market Cap 
1.50B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 8.85 
20-SMA 8.14 
50-SMA 7.18 
52-W High 10.94 
52-W Low 4.155 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.16/-1.90
Enterprise Value
1.59B
Balance Sheet
Book Value Per Share
4.87
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
66.52M
Operating Revenue Per Share
0.33
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.1048+0.0008+0.77%-- 
After Hours 0.1025 -0.0023 -2.19%
IBOImpact BioMedical Inc.0.6425+0.2292+55.46%-- 
After Hours 0.5603 -0.0822 -12.79%
TNYATenaya Therapeutics0.81955+0.23065+39.17%-- 
After Hours 0.7762 -0.04335 -5.29%
IOVAIovance Biotherapeutics4.595+0.355+8.37%-- 
After Hours 4.57 -0.025 -0.54%
GOSSGossamer Bio0.5218-0.0579-9.99%-- 
After Hours 0.514 -0.0078 -1.49%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.